Navigation Links
IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals
Date:11/8/2013

nclude a NDD-CKD revenue model from an iron supplement perspective rather than a phosphate binder."Kasimov predicts approval (ESRD) next year. Price target raised to $22 from $14.

USMarketBuzz.com is an investment community that Focuses on MicroCap Securities. USMarketBuzz.com is an authorative authentic Google News Site and Leading Provider of Investment Awareness and Featured Company Profiles. If you would like more information regarding our news coverage solutions, please visit http://www.USMarketBuzz.com/ for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.USMarketBuzz.com/. Follow us on Facebook: https://www.facebook.com/usmarket.buzz Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PREPROMO to 27126. (SMS alerts are free, however data rates may apply, check your wireless plan for details.)

DISCLAIMER:  FNNewswire (FNNW) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNNW is NOT affiliated in any manner with MarketBuzz Reports, USMarketBuzz.com or any company mentioned herein.  The commentary, views and opinions expressed in this release by MarketBuzz Reports and USMarketBuzz.com are solely those of the MarketBuzz Reports & USMarketBuzz.com and are not shared by and do not reflect in any manner the views or opinions of FNNW. The companies that are discussed herein may or may not have approved the statements made in this release. FNNW is not liable for any investment decisions by its readers or subscribers FNNW and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a regis
'/>"/>

SOURCE FN Media Group, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
2. Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30%
3. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
4. WuXi PharmaTech Schedules Second-Quarter 2012 Earnings Release
5. Life Technologies Sets 2nd Quarter 2012 Earnings Release Date for Tuesday, July 31, 2012
6. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
7. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations
8. Cambrex Reschedules Third Quarter 2012 Financial Results and Earnings Call Date to November 5, 2012
9. Sigma-Aldrich Announces Q4 2012 Earnings Conference Call
10. Zynga, Inc. Fourth-Quarter Earnings and Sales Topped Wall Street Estimates
11. PAREXEL Announces Date of Third Quarter Fiscal Year 2013 Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... / Japan (Q2 2015: +14% CER / ... on high-single-digit growth in China , as well as solid ... . Europe / Middle East ... sales) showed gains in Germany , Turkey ... +4% CER / 49% of sales) grew 11%, excluding U.S. HPV sales, on ...
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... -- Indivior PLC (LON: INDV) today announced that the New ... and received Priority Review by the U.S. Food and ... This naloxone nasal spray comes as a pre-filled device ... the nasal mucosa. 1 The device has been ... better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ formalized ... specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, and ... PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... Enhances ... Senior Management Team, ROCKVILLE, Md., June 18 EntreMed, ... the treatment of cancer and inflammatory diseases, today,announced the appointment ... and Business Development. Mr. Bliss has been elected,an executive officer ...
... Access to data may provide potential for label expansion ... Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTA) announced today ... Bayer,s phase III Zevalin(R) ([90Y]-ibritumomab,tiuxetan) First-line Indolent Trial, FIT ... be appropriate for CTI to begin discussions with the,U.S. ...
... IPC The,Hospitalist Company, Inc. (Nasdaq: IPCM ), ... guidance for full year 2008,revenue to be in the ... year,2008 earnings per adjusted pro-forma fully diluted share (excluding ... IPO) to be in the,range of $0.87 to $0.94. ...
Cached Biology Technology:EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 2EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 3EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 2CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 3CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 5CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 6IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 2IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 3IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 4
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... Researchers from the Institute of Food Research and The ... a gut bacterium, to help understand how these organisms ... relationship between gut bacteria and the gastrointestinal tract is ... the role of bacteria in establishing and maintaining gut ...
... , Higher temperatures could significantly impact California and other ... next 30 years, according to a new study led ... June 30 edition of Environmental Research Letters , ... land suitable for cultivating premium wine grapes in high-value ...
... BALTIMORE, June 29, 2011 BD Biosciences, a ... today the availability of BD Recharge™, a chemically ... manufacturing that offers productivity comparable to yeast-based peptones. ... significant advance for biopharmaceutical cell culture," said Robert ...
Cached Biology News:Genome analysis will reveal how bacteria in our guts make themselves at home 2Global warming could alter the US premium wine industry in 30 years, says Stanford study 2Global warming could alter the US premium wine industry in 30 years, says Stanford study 3Global warming could alter the US premium wine industry in 30 years, says Stanford study 4BD Biosciences Introduces Chemically Defined Cell Culture Media Supplement that Increases Biopharmaceutical Protein Production 2
For microscopy...
... fully automated hybridization of microarrays on slides. ... designed to offer researchers improved reproducibility, superior ... a wide range of applications. Incubations ... denaturations of up to 99C. The possibility ...
... slide processing offering reproducibility, reliability and ... miniaturization, automation and massive parallel analysis ... with many applications in both industrial ... from gene expression profiling, gene regulation ...
... Eppendorf Thermomixer R offers maximum application ... shaking, heating, and cooling. Its active ... application and temperature control ranges. Five ... 24 micro test tubes, are available ...
Biology Products: